December 3, 2017 – By Dolores Ford
Investor confidence increased to 1.03 in the second quarter of 2017. It is up 0.14, from 0.89 in 2017Q1. It increased, as 41 investors sold BSX shares, while 173 reduced their holdings. 56 funds opened positions, while 165 increased positions. 1.22 billion shares or 0.64% less than 1.23 billion shares in 2017Q1 were reported. Airain Ltd has 15,235 shares per 0.02% of its portfolio. Cleararc Cap owns 0.15% or 33,576 shares in its portfolio. Greenwood Assocs Ltd accumulated 0.38% or 53,330 shares. Tci Wealth, an Arizona-based fund reported 2,561 shares. Estabrook Cap has invested 0% in Boston Scientific Corporation (NYSE: BSX). Icon Advisers Inc has invested 0.47% in Boston Scientific Corporation (NYSE: BSX). Bankshares Of Montreal can report 576,861 shares. In addition, Sterling Cap Management Limited Com has a 0.08% investment in Boston Scientific Corporation (NYSE: BSX) for 306,649 shares. Lockheed Martin Inv Mngmt holds a 0.21% stake in Boston Scientific Corporation (NYSE: BSX) for 137,000 shares. Atalanta Sosnoff Cap Ltd Liability has invested 1.21% of its portfolio in Boston Scientific Corporation (NYSE: BSX). 2.90M were accumulated by Federated Invsts Pa. In addition, Continental Ltd Liability Corporation has a 0.42% stake in Boston Scientific Corporation (NYSE: BSX) for 67,100 shares. 27,060 were accumulated by Advisor Partners Ltd Co. Eaton Vance Mngmt accumulated 0.23% or 3.14 million shares. Winslow Evans Crocker stated that he has 680 shares or 0% of all his holdings.
As of June 1, 2017, it had 0 insider purchases and 1 insider sale for $ 379,736 of activity. Pratt Timothy A. sold shares valued at $ 271,261 or 10,000 shares.
Samuel Isaly decreased its stake in Boston Scientific Corp (BSX) by 5.95% based on its latest 2017Q2 regulatory report with the SEC. Orbimed Advisors Llc sold 911,400 shares, as the company's shares rose 4.02% with the market. The hedge fund managed by Samuel Isaly had 14.40 million shares of the medical and dental instrument company at the end of 2017Q2, valued at $ 399.17M, below the 15.31M at the end of the quarter previously reported. Orbimed Advisors Llc, which had been investing in Boston Scientific Corp for several months, appears to be less optimistic than the company with a market capitalization of $ 35.91B. The share declined 0.49% or $ 0.13 during the last trading session, reaching $ 26.15. Around 16.18 million shares traded or 148.41% more than the average. Boston Scientific Corporation (NYSE: BSX) has risen 19.12% since December 3, 2016 and is trending upward. It has surpbaded the S & P500 by 2.42%.
Orbimed Advisors Llc, which manages around $ 6.70B and $ 9.54 billion of portfolio in the United States, increased its stake in Global Blood Therapeutics In by 1.09 million shares to 2.17 million shares, valued at 59, 40 million dollars. 2017Q2, according to the presentation. It also increased its stake in Humana Inc (NYSE: HUM) by 28,600 shares in the quarter, for a total of 770,900 shares, and has increased its stake in Medtronic Plc (NYSE: MDT).
Analysts await Boston Scientific Corporation (NYSE: BSX) to report earnings on February 1. They expect earnings per share of $ 0.34, up to 13.33% or $ 0.04 of the $ 0.3 per share last year. The BSX gain will be $ 466.89 million for 19.23 P / E if the EPS of $ 0.34 becomes reality. After real earnings per share of $ 0.31 reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts EPS growth of 9.68%.
The latest notable news from Boston Scientific Corporation (NYSE: BSX) was published by: Prnewswire.com, which launched: "Boston Scientific will participate in the 2017 Citi Global Healthcare Conference" on November 27, 2017, also Prnewswire .com with your article: "Boston Scientific will participate in the 26th annual Credit Suisse Healthcare …" published on November 6, 2017, Globenewswire.com published: "Global Wearable Computing Market 2017-2022 with Medtronic, Garmin, Boston … "on November 17, 2017. More interesting news about Boston Scientific Corporation (NYSE: BSX) was released by: Nasdaq.com and its article:" Associated Banc-corp buys Boston Scientific Corp, Analog Devices Inc … "published on November 13, 2017, as well as from Prnewswire.com news article titled:" Boston Scientific announces the LOTUS Edge "aortic valve system update" with publication date: November 29, 2017 .
Ratings Coverage of Boston Scientific Corporation (NYSE: BSX)
Amo ng 28 badysts covering Boston Scientific Corporation (NYSE: BSX), 23 are Buy, 0 Sell and 5 Hold. Therefore, 82% are positive. Boston Scientific Corporation had 78 badyst reports from July 27, 2015 in accordance with SRatingsIntel. The qualification was maintained by Needham on Wednesday, June 28 with "Buy". Stifel Nicolaus held the shares of BSX in the report on Thursday October 26 with the rating of "Buy". The firm has a "Purchase" rating granted on Monday, June 19 by BMO Capital Markets. Goldman Sachs raised the rating of shares to "Neutral" in the report on Thursday, August 27. The qualification was maintained by Oppenheimer with "Suspension" on Wednesday, August 9. The firm has a "Purchase" rating granted on Wednesday, October 11 by BMO Capital Markets. Needham maintained the shares with a "Buy" rating in the report on Wednesday, October 28. The firm has a "Corporate" rating granted on Thursday, October 29 by FinnCap. The firm has a "Buy" rating granted on Thursday, February 25 by SunTrust. RBC Capital Markets maintained it with an "Outperform" rating and a target of $ 31 on Friday, June 9, report.
Receive news and ratings via email – Enter your email address below to receive a concise daily summary of the latest news and badysts & ratings with our FREE daily newsletter via email.